logoAiPathly

Allurion Technologies

A

Overview

Allurion Technologies Inc., listed on the NYSE under the ticker symbol ALUR, is a company dedicated to addressing obesity through innovative medical, digital, and nutritional solutions. Founded in 2009 by Shantanu Gaur and Samuel Levy, then Harvard Medical School students, Allurion's mission is to end obesity globally by providing a comprehensive weight-loss program that empowers patients to make lifelong healthy choices. The core of Allurion's offering is the Allurion Program, which includes:

  • Elipse Gastric Balloon: A swallowable, procedure-less intragastric balloon that helps patients lose 10-15% of their body weight in 16 weeks.
  • AI-Powered Remote Patient Monitoring: Utilizing advanced technology for continuous patient care.
  • Proprietary Behavior Change Program: Designed to help patients adopt and maintain healthy habits.
  • Secure Messaging and Video Telehealth: Provided through the Allurion Virtual Care Suite. The Allurion Program is backed by clinical evidence, demonstrating its safety and efficacy. Over 100,000 balloons have been distributed worldwide, showing significant weight loss results and improvements in metabolic syndrome. Headquartered in Natick, Massachusetts, Allurion Technologies is led by Dr. Shantanu Gaur, who serves as the Co-Founder, CEO, President, and Principal Financial and Accounting Officer. The company is recognized as a great place to work, with 85% of employees stating it is a positive work environment. Operating in the healthcare sector, specifically within the medical devices industry, Allurion has approximately 504 employees globally. The company is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol ALUR and actively files with the SEC, including recent amendments to their registration of securities.

Leadership Team

Allurion Technologies boasts a diverse and experienced leadership team driving its mission to end obesity. Key members include: CEO and Founder

  • Shantanu Gaur: Co-founder and CEO since 2018, Dr. Gaur holds an M.D. from Harvard Medical School and a B.S. in Biology from Harvard College. He has been with the company for over 15 years. Executive Leadership
  • Chris Geberth: Chief Financial Officer
  • Ram Chuttani: Chief Medical Officer, with a background as Director of Endoscopy at Beth Israel Deaconess Medical Center
  • Ojas A. Buch: Chief Operating Officer, appointed in June 2024
  • Brendan Gibbons: Chief Legal Officer and Corporate Secretary, appointed in January 2024 Board of Directors
  • Douglas Hudson: Recently appointed, a serial healthcare entrepreneur with experience in consumer-facing healthcare ventures
  • Michael Davin: Board member since October 2017, with experience as a director in various healthcare and technology companies
  • Nicholas Lewin: Director with experience as an investor in innovative healthcare and medical device companies
  • Keith Johns: Eli Lilly veteran, bringing extensive pharmaceutical industry experience Other Key Roles
  • Tomer Stavitsky: Vice President of Corporate Development, focusing on M&A and partnership strategy in AI and digital health The leadership team combines deep expertise in healthcare, technology, and business management, positioning Allurion Technologies for continued growth and innovation in the weight loss and healthcare sectors.

History

Allurion Technologies, the company behind the innovative Allurion gastric balloon and comprehensive weight-loss program, has a rich history dating back to its founding in 2009. Founding and Early Years

  • Founded in 2009 by Shantanu Gaur and Samuel Levy, then students at Harvard Medical School
  • Driven by patient stories, the founders developed a more accessible and convenient weight-loss solution Product Development
  • Created the Allurion Program, a full-stack weight-loss platform including:
    • Allurion Balloon: A swallowable, procedure-less intragastric balloon
    • Allurion Virtual Care Suite: AI-powered digital therapeutic and remote patient monitoring solution
    • Proprietary behavior change program Regulatory Approvals and Clinical Studies
  • Received CE-mark for the Allurion Balloon in 2015
  • Conducted extensive clinical studies, demonstrating significant weight loss results Global Expansion
  • Expanded operations to over 60 countries
  • Treated more than 100,000 patients
  • Launched in new markets including Canada, Mexico, India, Australia, and Brazil in 2022 Financial Growth and Public Listing
  • Revenue growth from $20 million in 2020 to $64 million in 2022
  • Announced business combination with Compute Health Acquisition Corp in February 2023
  • Became publicly listed on the New York Stock Exchange under the symbol 'ALUR' Leadership and Board Development
  • Dr. Shantanu Gaur serves as CEO
  • Board of directors includes experienced professionals from various sectors Allurion Technologies continues to innovate and expand its reach, addressing one of the world's largest unmet medical needs through its mission to end obesity globally.

Products & Solutions

Allurion Technologies offers a comprehensive suite of products and solutions aimed at addressing obesity and promoting long-term weight loss:

Allurion Program

The core offering combines medical, digital, and nutritional approaches to weight loss:

  • Allurion Gastric Balloon (Elipse™): A swallowable, procedure-less intragastric balloon that helps patients lose 10-15% of their body weight in 16 weeks. This non-invasive solution addresses the need for weight loss without traditional surgery.

AllurionMeds

A recently launched program integrating GLP-1 medications with AI-powered support:

  • GLP-1 Medications: Sourced from FDA-registered 503b facilities and delivered directly to patients' homes.
  • Coach Iris: An AI-native platform providing 24/7 coaching and support for medication adherence and healthy behaviors.
  • Virtual Dietician Access: Patients can consult with dieticians virtually to support their weight loss journey.
  • Connected Smart Scale: Measures weight, muscle, and bone mass for comprehensive monitoring.

Allurion Virtual Care Suite

A set of digital tools supporting weight loss and health management:

  • Allurion Mobile App: Provides ongoing support and tracking for consumers.
  • Allurion Insights: Offers healthcare providers tools to customize, monitor, and manage patient weight loss therapy.
  • Allurion Connected Scale: Integrates with the mobile app and AI platform for comprehensive health metrics.

Additional Features

  • Expanded Services: Available in all 50 U.S. states with plans to offer a broader range of GLP-1 medications.
  • Clinical Research: The Allurion Program is backed by extensive studies on safety and efficacy. Allurion Technologies' holistic approach combines innovative medical technologies with digital and nutritional support, aiming to help patients achieve and maintain significant weight loss.

Core Technology

Allurion Technologies' core technology revolves around its comprehensive weight loss platform, the Allurion Program. Key components include:

Allurion Balloon

The world's first and only swallowable, procedure-less intragastric balloon for weight loss. This innovative device:

  • Is ingested orally and expands in the stomach
  • Helps reduce hunger and facilitate weight loss
  • Requires no surgery or endoscopy

Virtual Care Suite (VCS)

An AI-powered digital therapeutic and remote patient monitoring solution comprising:

  1. Allurion App:
    • Provides access to a proprietary behavior change program
    • Offers over 150 weight loss actions related to diet, nutrition, mental health, sleep, and goal setting
    • Available in over 15 languages
  2. Allurion Insights:
    • Clinic dashboard for healthcare providers
    • Offers end-to-end remote patient monitoring
    • Utilizes AI-powered tools, including the Iris AI platform
    • Leverages machine learning for key insights and workflow streamlining
  3. Connected Scale and Health Tracker:
    • Monitors weight, body fat, activity, sleep, and other critical metrics
    • Integrates data into the Allurion App and VCS

AI-Enabled Support

  • Coach Iris: Part of the AllurionMeds program
  • Combines GLP-1 medications with virtual dietician access
  • Provides AI-driven coaching for long-term weight maintenance

Integrated Care

The Allurion Program integrates:

  • Secure messaging
  • Video telehealth visits
  • Remote patient monitoring
  • Treatment tracking
  • Clinic-led onboarding These features support various weight loss treatments, including gastric balloons, surgery, and medications. Allurion Technologies' core technology uniquely combines innovative medical devices, AI-powered digital therapeutics, and comprehensive patient support to create a holistic weight loss platform.

Industry Peers

Allurion Technologies operates in the medical equipment and supplies industry, competing with several notable companies:

Direct Competitors

  1. Sensus Healthcare (NASDAQ: SRTS): Focused on radiation oncology and non-invasive treatments
  2. TELA Bio (NASDAQ: TELA): Develops tissue reinforcement materials
  3. electroCore (NASDAQ: ECOR): Specializes in non-invasive vagus nerve stimulation therapies
  4. LENSAR (NASDAQ: LNSR): Develops laser cataract surgery systems
  5. Fractyl Health (private): Creates minimally invasive interventions for metabolic diseases
  6. FONAR (NASDAQ: FONR): Known for MRI technology, particularly the UPRIGHT MRI
  7. Monogram Orthopaedics (private): Develops personalized orthopedic implants
  8. Edap Tms (NASDAQ: EDAP): Specializes in minimally invasive medical devices for urology and oncology
  9. Milestone Scientific (NYSE: MLSS): Develops dental and medical injection technologies
  10. Vivani Medical (private): Focuses on various therapeutic areas

Other Industry Peers

  1. MED-EL: Develops cochlear implants and hearing solutions
  2. Otto Bock HealthCare: Specializes in prosthetics, orthotics, and mobility solutions
  3. Smith & Nephew: Multinational company offering orthopedics, sports medicine, and advanced wound management products
  4. Terumo Medical: Develops medical devices including cardiovascular systems and general hospital products
  5. IRIDEX (NASDAQ: IRIX): Focuses on ophthalmic laser-based medical products
  6. DarioHealth (NASDAQ: DRIO): Develops digital health solutions for chronic conditions
  7. Beyond Air (NASDAQ: XAIR): Specializes in nitric oxide-based therapies for respiratory diseases These companies operate within the broader medical equipment and supplies sector, often competing or complementing Allurion Technologies in various market segments. While some focus on specific areas like orthopedics or ophthalmology, others offer a range of medical solutions that may overlap with Allurion's weight loss and health monitoring technologies.

More Companies

E

Enfusion

Enfusion is a global, high-growth Software-as-a-Service (SaaS) provider that specializes in transforming the investment management industry. The company's cloud-native platform unifies front, middle, and back-office operations, offering a comprehensive solution for asset managers and institutional investors. Key aspects of Enfusion's platform include: 1. Cloud-Native Architecture: Designed for scalability, flexibility, and continuous improvement, featuring a multi-tenant structure that enables weekly, disruption-free updates. 2. Unified Data Management: Utilizes a single, unified dataset as a source of truth, ensuring all stakeholders have access to consistent, up-to-date information. 3. Comprehensive Modules: - Portfolio Management: Includes real-time Investment Book of Record (IBOR), valuation and risk tools, and portfolio data aggregation. - Order and Execution Management System (OEMS): Offers FIX connectivity, compliance technology, and access to over 200 executing brokers. - Analytics: Centralizes live, historical, and third-party data for investment ideation and automated reporting. - Accounting: Features a double-entry general ledger with automated posting, maintaining a real-time Accounting Book of Record (ABOR). 4. Managed Services and Support: Provides dedicated middle- and back-office services, along with in-region account managers and a global support team. 5. Integration and Connectivity: Offers easy integration with internal and third-party systems via API, FIX connectivity, and real-time market data streaming. Benefits of Enfusion's platform include simplified investment and operational workflows, reduced maintenance costs, and enhanced focus on investment performance. The cloud-native architecture allows clients to scale easily and enter new asset classes effortlessly. Enfusion has garnered industry recognition, including awards for Best EMS/OMS Provider and Best Institutional Investment Solution. The company serves over 800 investment managers across nine global offices spanning four continents, solidifying its position as a leader in investment management solutions.

I

Inari Medical

Inari Medical is a pioneering medical device company dedicated to treating and transforming the lives of patients suffering from venous diseases, with a particular focus on venous thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). ### Mission and Products The company's mission centers on improving patient outcomes through innovative devices. Their product portfolio includes: - **FlowTriever System**: A large bore catheter-based aspiration and mechanical thrombectomy system for removing large clots from venous vessels, the right heart, pulmonary arteries, and lungs. FDA-approved for Pulmonary Embolism (PE) treatment in 2018 and Right Atrial Clot in Transit in 2021. - **ClotTriever System**: Designed to core, capture, and remove large clots from large venous vessels. Received FDA 510(k) market clearance in 2017 for non-surgical removal of thrombi and emboli from peripheral vasculature. ### Clinical Research and Market Presence Inari Medical demonstrates a strong commitment to clinical data generation through studies and registries such as FLARE, CLOUT, FLASH, FLAME, and PEERLESS. The company operates in multiple countries, including the US, Switzerland, Singapore, Canada, Australia, Brazil, the UK, and Ireland, with a rapidly expanding sales team. The estimated addressable market in the US alone is $5.8 billion, with significant international opportunities. ### Financial Performance and Recent Developments Since its successful IPO in May 2020, Inari Medical has shown robust quarterly revenue growth with gross margins exceeding 80%. Recent developments include: - Securing national reimbursement approval in Japan for the ClotTriever Thrombectomy System (December 2024) - Entering a joint venture to introduce devices in Greater China - Partnering with the American Venous Forum and the National Blood Clot Alliance on the DEFIANCE trial ### Commitment to Healthcare Inari Medical is dedicated to establishing its treatments as the standard of care for VTE and related conditions through innovative solutions, education, clinical research, and program development. Their ethos, "Patients first. Always," underscores their commitment to improving patient outcomes and transforming lives affected by venous diseases.

D

DataDirect Networks

DataDirect Networks (DDN) is a privately held data storage company headquartered in Chatsworth, California, USA. Founded in 1998, DDN has established itself as a leader in high-performance storage solutions for data-intensive applications. History and Founding: DDN was formed through the merger of MegaDrive and ImpactData. The company's co-founders, Alex Bouzari (CEO and Chairman) and Paul Bloch (President), continue to lead the organization. Products and Solutions: DDN specializes in storage systems for unstructured data and big data applications, particularly in AI, analytics, and high-performance computing (HPC). Their product lineup includes: - Data management solutions - Network-attached storage (NAS) - Block data storage - Clustered file systems - Object storage These solutions offer low latency, high capacity, and sustained throughput for data-intensive applications. Market Presence: DDN serves over 11,000 customers across enterprise, government, and academia sectors in more than 50 countries. Notable clients include NASA, Nvidia, Argonne National Laboratory, and leading financial services firms. Financial Performance: In 2020, DDN reported annual revenues of $400 million, marking its highest profitability and fifth consecutive year of growth. Between 2018 and 2020, the company experienced a 52% revenue increase. Strategic Acquisitions: DDN has expanded its capabilities through key acquisitions, including: - Lustre filesystem storage team from Intel (2018) - Tintri, a virtualization-focused storage company (2018) - Nexenta, a software-defined storage vendor (2019) - IntelliFlash division from Western Digital (2019) Innovation and R&D: With approximately two-thirds of its staff in R&D and customer-facing technical roles, DDN has increased its R&D budget by 65% between 2018 and 2020. The company holds over 150 patents and continues to innovate in data intelligence and storage solutions. AI and HPC Focus: DDN is particularly renowned for accelerating AI and HPC workloads. Its Data Intelligence Platform handles massive data sets from edge to core to cloud, enabling real-time analysis and advanced learning. DDN's solutions support over 500,000 GPUs, delivering 100% GPU utilization and faster AI application acceleration. In summary, DataDirect Networks is a leading provider of high-performance storage solutions, with a strong global presence and a commitment to innovation in AI, HPC, and data-intensive applications.

I

Investcorp

Investcorp is a global investment manager specializing in alternative investments, founded in 1982 by Nemir A. Kirdar. The firm has grown from its roots in the Gulf to become a major player in the global investment landscape. ### Business Lines Investcorp operates across several key business lines: - Private Equity: Focuses on mid-market investments, particularly in North America, targeting services-oriented companies with strong growth potential. - Real Estate: Invests in global real estate opportunities. - Absolute Return Strategies: Offers investors exposure to a broader array of investment opportunities. - Credit Management: Launched in 2017 as part of its global growth strategy. - Infrastructure: Entered through a joint venture with Aberdeen Standard Investments. - Strategic Capital: Invests in mid-sized alternative investment managers. ### Growth and Global Presence Investcorp has experienced significant growth, with Assets Under Management (AUM) increasing from $10 billion to over $50 billion in the past six years, reaching $53 billion as of June 30, 2024. The firm has expanded its global presence with offices in key locations such as New York City, London, Riyadh, Abu Dhabi, Doha, Singapore, and Mumbai. ### Investment Approach Investcorp is known for its disciplined investment approach, acting as a strategic partner to its portfolio companies. The firm focuses on organic growth, mergers and acquisitions, enhancing team and organization, and improving efficiency and infrastructure. ### ESG and Corporate Responsibility Investcorp places a strong emphasis on Environmental, Social, and Governance (ESG) factors, integrating ESG considerations into its due diligence processes and ongoing investment support. ### Leadership As of the latest information, Mohammed Alardhi serves as the Executive Chairman, leading the firm's global growth strategy and overseeing its continued expansion and commitment to sustainable value creation. Investcorp has established itself as a trusted global alternative asset manager, known for its superior performance, diverse asset classes, and commitment to ESG and corporate responsibility.